ACP
REPL icon

Acuta Capital Partners’s Replimune Group REPL Stock Holding History

Acuta Capital Partners’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$1.77M – 52
2023
Q3 		$1.77M Buy
+1,000
New +$19.6K 1.18% 28

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acuta Capital Partners's REPL Position: Q4 2023 in Review

Acuta Capital Partners sold out of Replimune Group (REPL) in Q4 2023, closing a stake of 150,000 shares — an estimated $2.57M sold.

Acuta Capital Partners first reported a position in REPL in Q4 2020 and held it in 2 quarters. The position peaked at $7.92M in Q4 2020. 140 funds tracked by Wall St. Rank hold REPL as of Q4 2023.

  • Acuta Capital Partners reported no remaining Replimune Group position as of Q4 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 150,000 Replimune Group shares in Q4 2023, an estimated $2.57M.
  • Acuta Capital Partners first reported a position in Replimune Group in Q4 2020 and held it in 2 quarters.
  • Acuta Capital Partners's Replimune Group position peaked at $7.92M in Q4 2020.
  • 140 funds tracked by Wall St. Rank held Replimune Group as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.